Announcements Trials

Browse Landscape

Phase

Status

Completed 12 Recruiting 2 Withdrawn 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 3 Urinary Bladder Neoplasms 2 Inflammatory Breast Neoplasms 2 Carcinoma, Transitional Cell 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma 1 Liposarcoma 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 Colorectal Neoplasms 1

Interventions

Radiotherapy 11 pembrolizumab 10 Nivolumab 10 Doxorubicin 10 Magnetic Resonance Spectroscopy 9 Specimen Handling 8 Cyclophosphamide 8 Biopsy 7 X-Rays 6 Ipilimumab 6 Radiation 5 Phantoms, Imaging 5 Ifosfamide 5 talimogene laherparepvec 4 cabozantinib 4 Nuclear Medicine Department, Hospital 4 Irinotecan 4 tazemetostat 3 selpercatinib 3 pazopanib 3 liposomal doxorubicin 3 fludarabine 3 Temozolomide 3 Etoposide 3 ulixertinib 2 tislelizumab 2 tipifarnib 2 palbociclib 2 larotrectinib 2 ivosidenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × eribulin × Clear all

NCT06263231 2025-07-29

INVINCIBLE-3

Intensity Therapeutics, Inc.

Phase 3 Active not recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡